Loading company
Oric Pharmaceuticals, Inc.
ORIC · Nasdaq · ·
$13.35+0.8%Sep 29 close
- 1M
- +0.8%
- 6M
- +9.5%
- 1Y
- +11.2%
- 5Y
- -42.0%
ORIC · Nasdaq · ·
$13.35+0.8%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$41.5M | -$36.4M | -14.13% |
| Profit per share | -$0.38 | -$0.47 | +19.15% |
| Free Cash Flow | -$32M | -$30.9M | -3.42% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Oric Pharmaceuticals, Inc. has no earnings call transcript available.
“The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially practice-changing therapy for patients with prostate cancer,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer . ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Oric Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.